1375. In vitro Activity of Cefiderocol and Comparator Agents against Gram-negative Isolates from Cancer Patients
Session: Poster Abstract Session: Novel Agents
Friday, October 5, 2018
Room: S Poster Hall
  • IDSA 2018 - Cefiderocol Redo.pdf (943.8 kB)
  • Background:

    Gram-negative bacilli (GNB) are now the predominant cause of bacterial infection in cancer patients (CP). Many GNB are problematic because they have become resistant to commonly used antibiotics. Cefiderocol (CFDC), a novel siderophore cephalosporin, is active against a wide spectrum of GNB. We evaluated its in vitro activity and that of eleven comparator agents against GNB isolated from CP.


    341 recent GNB blood isolates from CP were tested using CLSI approved methods for MIC determination by broth microdilution. Comparator agents were amikacin (A), aztreonam (AZ), ceftazidime (CZ), ceftazidime/avibactam (CAV), cefepime (CEF), ciprofloxacin (CIP), colistin (CL), meropenem (MR), ceftolozane/tazobactam (C/T), tigecycline (TG), and trimethoprim/sulfamethoxazole (T/S).


    CFDC MIC90s as mg/L were: S. maltophilia [50 isolates] 0.25, E. coli (ESBL-) [50 isolates] 0.5, E. coli (ESBL+) [51 isolates] 2.0, K. pneumoniae (ESBL- and +) [60 isolates] 0.5; K. pneumoniae (CRE) [22 isolates] 2.0; P. aeruginosa (MDR) [32 isolates] 1.0; E. cloacae [27 isolates] 4.0; Achromobacter spp [15 isolates] 0.12. CFDC inhibited P. agglomerans, Burkholderia spp, Sphingomonas spp, Ochrobactrum spp at ≤1 mg/L [23 total isolates] and Elizabethkingia spp and R. radiobacter at ≤8 mg/L [11 total isolates]. Among comparator agents, only T/S had consistent activity against S. maltophilia. For E. coli (ESBL- and +) MR, TG, CAV, CL were most active. For K. pneumoniae (ESBL – and +) MR, CAV were most active. For K. pneumoniae (CRE) and P. aeruginosa (MDR), none of the comparators had significant activity. For E. cloacae, MR, A, CAV, TG were most active. Among the uncommon organisms, MR and TG had the greatest activity.


    Although susceptibility breakpoints have yet to be determined, CFDC has significant activity (≤4 mg/L) against most problematic gram-negative organisms causing infections in CP based on available pharmacokinetic/pharmacodynamic data. In particular, its activity against S. maltophilia was superior to the comparators. Also, it was the most active agent against P. aeruginosa (MDR) and K. pneumoniae (CRE). Based on our results, CFDC warrants clinical evaluation for the treatment of blood stream infections caused by GNB in CP.

    Kenneth V.I. Rolston, MD1, Bahgat Gerges, PhD1, Issam Raad, MD2, Samuel L. Aitken, PharmD3,4, Ruth Reitzel, PhD1 and Randall Prince, PharmD, FIDSA1, (1)Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, (2)The University of Texas MD Anderson Cancer Center, Houston, TX, (3)Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, (4)Center for Antimicrobial Resistance and Microbial Genomics (CARMiG), UTHealth McGovern Medical School, Houston, TX


    K. V. I. Rolston, Merck: Investigator , Research grant . JMI Laboratories: Investigator , Research grant . Shionogi (Japan): Investigator , Research grant .

    B. Gerges, Shionogi: Collaborator , Research support .

    I. Raad, None

    S. L. Aitken, Shionogi: Scientific Advisor , Consulting fee . Merck: Scientific Advisor , Consulting fee . Medicines Co: Scientific Advisor , Consulting fee . Achaogen: Scientific Advisor , Consulting fee . Zavante: Scientific Advisor , Consulting fee .

    R. Reitzel, None

    R. Prince, Shionogi: Investigator , Research support . Merck: Investigator , Research support .

    See more of: Novel Agents
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.